Overview |
bs-0633R-Cy5 |
CDK4 Polyclonal Antibody, Cy5 Conjugated |
WB, FCM, IF(IHC-P), IF(IHC-F), IF(ICC) |
Human, Mouse, Rat, Sheep |
Cow, Pig |
Specifications |
Cy5 |
Rabbit |
KLH conjugated synthetic peptide derived from human CDK4 |
241-303/303 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
Target |
1019 |
P11802 |
Cytoplasm, Nucleus, Cell membrane |
CMM3; PSK-J3; Cyclin-dependent kinase 4; Cell division protein kinase 4; CDK4 |
Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes that phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complexes and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also phosphorylates SMAD3 in a cell-cycle-dependent manner and represses its transcriptional activity. Component of the ternary complex, cyclin D/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex. |
Application Dilution |
WB |
1:300-5000 |
FCM |
1:20-100 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |